| Name | Title | Contact Details |
|---|---|---|
Patrick Treacy |
Chief Executive Officer | Profile |
Burton is a subsidiary and medical arm of Luxo ASA of Oslo, Norway. Burton is a wholly-owned subsidiary corporation located in Chatsworth, California, just north of Los Angeles, where all lights are manufactured in its 35,000 square foot facility. Burton
Pennsylvania Occupational Therapy Association (POTA) is a Harrisburg, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Leis Medical is a Vandalia, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company`s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Approximately 1.7 million Americans have AAA, and the incidence of the condition increases with age. Endologix is currently marketing the AFX® Endovascular AAA System is available in the U.S., Europe, Latin America and other regions. The Nellix® EndoVascular Aneurysm Sealing System, a novel aneurysm sealing system, is approved for sale in Europe and other markets and for investigational use in the U.S. The Powerlink with IntuiTrak® Delivery System is available in Japan. These technologies are minimally invasive, allowing for greater patient comfort and quicker recovery compared to invasive surgical alternatives. Endologix products are protected by at least 52 U.S. patents with at least 956 allowed claims. Endologix is a publicly-held company trading on NASDAQ: ELGX. The Company`s corporate office is located in Irvine, California.
In 1993, a novel technology was invented by a team that included Jon Faiz Kayyem, PhD at The California Institute of Technology (CalTech). This invention combined nucleic acids and microelectronics to produce an electronic sensor for DNA detection. His invention was based on electrical detection of nucleic acids on a cassette based detection platform. Dr. Kayyem went on to found Clinical Micro Sensors, with the goal of translating this “eSensor” technology to disposable chips. Following several acquisitions of the technology, Dr. Kayyem became actively involved again in 2009, returning as an investor and then as CEO and Chairman of the Board. In 2009, a collaboration between Dr. Kayyem and Christopher Gleeson began. The two redefined the company strategy, and brought in a new board of directors, executive leadership team, and commercial management. In 2010, the company known at that time as Osmetech, was named GenMark Diagnostics and listed on NASDAQ. Mr. Gleeson remained an integral part of GenMark`s growth in the years that followed, serving as Chairman of the Board until his retirement in 2014. Dr. Kayyem currently serves as SVP, Research and Development.